Download as pptx, pdf, or txt
Download as pptx, pdf, or txt
You are on page 1of 30

MEASLES AND SCARLET

FEVER FATIN & EILEEN

KAWASAKI DISEASE
MEASLES Measles is a highly contagious,
serious disease caused by a
virus. (in the paramyxovirus
family)
Currently rare after
introduction of MMR vaccine
HOW IT IS SPREAD?It is normally passed through direct
contact and through the air.
Measles is so contagious that if one
person has it, up to 90% of the people
close to that person who are not immune
will also become infected.
Measles virus can live for up to two
hours in an airspace after an infected
person leaves an area.
KOPLIK
SPOTS
- WHITE SPOT
USUALLY
FOUND ON
BUCCAL
MUCOSA
-
PATHOGNOMONI
C BUT
DIFFICULT TO
SEE
Rash
Discrete maculopapular rash
Initially become blotchy and
confluent
It spreads downward from
behind of the ears to the face
and neck and spread to the
whole of the body
May desquamate in the second
week
TREATMENT OF MEASLES
No specific antiviral treatment for measles virus.
Severe complications from measles can be reduced through supportive care.
 that ensures good nutrition, adequate fluid intake and treatment of dehydration

Antibiotics should be prescribed to treat eye and ear infections, and pneumonia.
Vitamin A supplements can be given in 2 doses 24 hours apart. This treatment
restores low vitamin A levels during measles that occur even in well-nourished
children and can help prevent eye damage and blindness.
COMPLICATIONS OF MEASLES
Complications are more likely in children with a poor immune system, those who
are malnourished or children age under 5 years old.
Common complications
 Ear infections occur in about one out of every 10 children with measles.
 Diarrhea is reported in less than one out of 10 people with measles.

Severe complications
 Pneumonia : 1 out of every 20 children, the most common cause of death from measles in young
children
 Encephalitis : 1 out of every 1000 children, can lead to convulsion and can leave the child deaf or
mentally retarded.
Long-term Complications
 Subacute sclerosing panencephalitis (SSPE) is a very rare, but fatal
disease of the central nervous system that results from a measles virus
infection acquired earlier in life.
 SSPE generally develops 7 to 10 years after a person has measles, even
though the person seems to have fully recovered from the illness.
 Since measles was eliminated in 2000, SSPE is rarely reported.
SCARLET Scarlet fever (sometimes called scarlatina)
is an infectious disease caused by bacteria
FEVER called Streptococcus pyogenes, or group
A streptococcus (GAS)

SCARLE Scarlet fever is mainly a childhood


disease and is most commonly seen
T FEVER between the ages of 2 and 8 years.
Scarlet fever, is highly contagious and is
spread by close contact with someone
carrying the bacteria
SIGNS AND SYMPTOMS
It takes around 2 to 5 days to develop
symptoms after exposure to these
bacteria.
Characteristics of the rash typically
include:
 Erythematous rash that blanches on pressure
 Sandpaper quality
 Begins on the trunk, then quickly spreads
outward, usually sparing the palms, soles, and
face
TREATMENT OF SCARLET
FEVER
The use of a recommended antibiotic regimen to treat
scarlet fever:
Shortens the duration of symptoms
Reduces the likelihood of transmission to family members,
classmates, and other close contacts
Prevents the development of complications, including acute
rheumatic fever
Penicillin V or amoxicillin is the antibiotic of choice to treat scarlet fever
KAWASAKI DISEASE
 systemic vasculitis
 Also called as mucocutaneous lymph node
syndrome
most important manifestation/complication
= coronary vasculitis  aneurysm of coronary
arteries
EPIDEMIOLOGY
Usually affect 6m to 4 y/o children
Peak: end of first year of life
boys>girls

Young infants
-more sevely affected
-Have incomplete sx
ETIOLOGY
Remains unknown
Possible bacterial toxin or viral agents with genetic predisposition
DIAGNOSTIC CRITERIA :
#WARMCREAM
 Warm : fever >5day

 Conjunctivitis : bilateral, non purulent


 Rash : erythematous, maculopapular,
 Erythema palm and sole : with swelling
 Adenopathy : cervical, unilateral
 Mucous membrane : dry, red, strawberry tongue
DIAGNOSTIC CRITERIA
Fever (at least 5d) + 4 out of 5 of the following:

EYE BILATERAL NON PURULENT


CONJUCTIVTIS
MUCOSAL CHANGES IN INJECTED PHARYNX
OROPHARYNX RED LIPS
DRY FISSURED LIPS
STRAWBERRY TONGUE
NECK CERVICAL
LYMPHADENOPATHY
BODY (TRUNCAL) RASH (POLYMORPHOUS BUT
NON VESICULAR)
CHANGES IN EXTREMITIES EDEMA HAND, FEET
ERYTHEMA
DESQUAMATION (BEGINNING
PERIUNGUALLY)
OTHER FEATURES
CNS IRRITABILITY
ALTERED MENTAL
STATE
ASEPTIC MENINGITIS
CVS CORONARY
ABNORMALITIES
GIT DIARRHEA
VOMITING
ABD PAIN
HEPATOSPLENOMEGALY
HYDROPS OF GALL
BLADDER
GU STERILE PYURIA
MUSCULOSKELETAL TRANSIENT ARTHRITIS
OTHERS INDURATED BCG SCAR
C A Adenopathy – cervical,
unilateral

R
M

E
INCOMPLETE KAWASAKI
DISEASE
Tend to occur in young infant
Have incomplete symptoms in which not fulfill diagnostic criteria
Must be high suspicious-can develop coronary artery dilatation or
aneurysm
INVESTIGATION
No diagnostic test
FULL BLOOD COUNT NORMOCYTIC ANEMIA
LEUCOCYTOSIS
THROMBOCYTOSIS
- AFTER 10TH DAY OF ILLNESS
- LAST FOR FEW WEEKS
LIVER FUNCTION TEST ELEVATED ALANINE
TRANSAMINASE
HYPOALBUMINEMIA
(ALBUMIN <3G/DL)
ACUTE PHASE REACTANTS ESR HIGH
CRP HIGH
URINE >10 WBC/HPF
ECHOCARDIOGRAPHY TO LOOK FOR/MONITOR
CORONARY ARTERY
ANEURYSM DEVELOPMENT
INDICATION OF ECHO
Prolong fever
With other 2 criteria
 Periungual desquamation
 2 criteria + thrombosis
 Rash without any other explaination
MANAGEMENT
Primary Tx
1. IV Immunoglobulin 2gm/kg infusion over 10-12h
- If start <10d of onsetprevent coronary vascular damage
2. Oral aspirin 30mg/kg/d (anti-inflammatory dose) for 2w or until afebrile for 2-3d

Maintainance
1. Oral Aspirin 3-5mg/kg/d (anti-platelet dose) for 6-8w or until ESR and platelet
normalize
2. If coronary artery aneurysm presentcont Aspirin until resolves
3. If develop giant coronary artery aneurysmlong term warfarin therapy

If not respond to primary tx,


-persistent or recrudescent fever 36 hrs and more after completion initial dose IV
Immunoglobulins

TX repeat IV Immunglobulins 2gm/kg infusion over 10-12h


VACCINATION
IV Ig impair efficacy live attenuated virus vaccine

So, need to delay these vaccination for at least 11 months


PROGNOSIS
1. Complete recovery in children without coronary artery involvement
2. 80% of 3-5mm aneurysm resolve
3. 30% of 5-8mm aneurysm resolve
4. Aneurysm>8mm (prognosis worst)
5. Mortality=1-2% (from cardiac complication within 1-2 months onset)
REFERENCES
ILLUSTRATED TEXT BOOK OF PAEDIATRIC, 5TH EDITION ,TOM LISEAUR
PAEDIATRIC PROTOCOL 4TH EDITION
DRUG DOSES FRANK SHAN

You might also like